Protara Therapeutics, Inc.
TARA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $32 | $25 | $17 | $21 |
| G&A Expenses | $17 | $19 | $21 | $26 |
| SG&A Expenses | $17 | $19 | $21 | $26 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $30 | $0 |
| Operating Expenses | $49 | $43 | $67 | $47 |
| Operating Income | -$49 | -$44 | -$67 | -$47 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $5 | $3 | $1 | $0 |
| Pre-Tax Income | -$45 | -$40 | -$66 | -$47 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$45 | -$40 | -$66 | -$47 |
| % Margin | – | – | – | – |
| EPS | -2.17 | -3.57 | -5.86 | -4.2 |
| % Growth | 39.2% | 39.1% | -39.5% | – |
| EPS Diluted | -2.17 | -3.57 | -5.86 | -4.2 |
| Weighted Avg Shares Out | 21 | 11 | 11 | 11 |
| Weighted Avg Shares Out Dil | 21 | 11 | 11 | 11 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $3 | $1 | $0 |
| Interest Expense | $0 | $0 | $1 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$49 | -$43 | -$65 | -$45 |
| % Margin | – | – | – | – |